KALW1h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
BioWorld7h
US FDA clears Cobenfy, first new schizophrenia drug in decades
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
GlobalData on MSN10h
BMS wins approval for schizophrenia drug acquired from Karuna
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
STAT15h
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...